Nitazoxanide


Concise Prescribing Info
Indications/Uses
Listed in Dosage.
Dosage/Direction for Use
Adult : PO Cryptosporidiosis; Giardiasis 500 mg 12 hrly for 3 days.
Dosage Details
Oral
Cryptosporidiosis, Giardiasis
Adult: 500 mg every 12 hr for 3 days.
Child: 1-3 yr: 100 mg every 12 hr; 4-11 yr: 200 mg every 12 hr; ≥12 yr: 500 mg every 12 hr. All doses to be taken for 3 days.
Administration
Should be taken with food.
Contraindications
Hypersensitivity.
Special Precautions
Renal and hepatic impairment. Pregnancy and lactation. Children <1 yr.
Adverse Reactions
Headache, abdominal pain, diarrhoea, nausea, vomiting, allergic reactions, anaemia, anorexia, increased appetite, increased creatinine and LFT, diaphoresis, dizziness, eye and urine discolouration, fever, flatulence, hypertension, infection, malaise, nausea, pruritus, rhinitis, enlarged salivary glands, tachycardia.
Drug Interactions
May possibly interact with highly protein-bound drugs e.g. warfarin.
Food Interaction
Increased AUC with food.
Action
Description: Nitazoxanide is an antiprotozoal agent. Both nitazoxanide and its active metabolite (tizoxanide) interfere with the pyruvate:ferredoxin 2-oxidoreductase (PFOR) enzyme-dependent electron transfer reaction which is essential to anaerobic metabolism in susceptible organisms.
Pharmacokinetics:
Absorption: Absorbed from the GI tract (oral). Extent of absorption enhanced with food; peak plasma concentrations of tizoxanide and glucuronide metabolite after 1-4 hr.
Distribution: Protein-binding: >99%.
Metabolism: Rapidly hydrolysed to tizoxanide (active desacetyl metabolite) which partially undergoes conjugation, primarily by glucuronidation.
Excretion: Via faeces (2/3 of an oral dose); via urine (remaining dose).
Storage
Suspension: Store at 15-30°C (59-86°F). Tablet: Store at room temperature.
MIMS Class
Disclaimer: This information is independently developed by MIMS based on Nitazoxanide from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in